Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has successfully completed a three-day...

Corgenix, Tulane Announce Award of NIH Grant Extending Hemorrhagic Fever Virus Product Development Program

Recent Lassa fever outbreaks in Africa show vital need for new products that can be processed in any clinical or field lab DENVER and NEW ORLEANS, May 7 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test ...

ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent

FREDERICK, Md., April 21 /PRNewswire/ -- ImQuest BioSciences and Arisyn Therapeutics jointly announced today the successful acquisition of funding from the National Institutes of Health to support the development of novel small molecule therapeutics for the treatment of hepatitis C virus (HCV) inf...

Franco Nuschese Tapped by Robert C. Gallo Foundation for AIDS and Virus Research

BALTIMORE, Feb. 2 /PRNewswire-USNewswire/ -- The Robert C. Gallo Foundation for AIDS and Virus Research today announced the appointment of Franco Nuschese as director of international relations. The foundation supports Dr. Gallo and his colleagues, who are internationally known for expertise in H...

Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

CAMBRIDGE, Mass., Jan. 12 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today announced that it has initiated a proof-of-concept...

Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate

Novavax's first vaccine candidate for the prevention of RSV ROCKVILLE, Md., Dec. 8 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today that Dr. Trudy Morrison, PhD, Professor of Molecular Genetics and Microbiology, University of Massachusetts Medical School , will b...

MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine

GAITHERSBURG, Md., Nov. 3 /PRNewswire/ -- MedImmune today announced that it has initiated a Phase 1/2a clinical trial of a live, attenuated intranasal vaccine in healthy children one month to 12 months of age to help prevent severe respiratory syncytial virus (RSV) infections. RSV is the most ...

DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties

Spraying Set for Tonight in Parts of Bucks, Delaware, Montgomery, Philadelphia Counties NORRISTOWN, Pa., Aug. 27 /PRNewswire-USNewswire/ -- After encouraging results following the first night of aerial treatments, the Department of Environmental Protection will continue its efforts this eveni...

Positive Mosquito Count for West Nile Virus Lead DEP, Southeastern PA Counties to Ramp up Treatment Activities

NORRISTOWN, Pa., Aug. 18 /PRNewswire-USNewswire/ -- Due to an exceptionally high number of West Nile virus-infected mosquitoes in southeastern Pennsylvania, the Department of Environmental Protection and its county partners will be stepping up efforts this week to combat the mosquito populatio...

Inverness Medical Innovations Receives USDA Licensure of the BinaxNOW(R) Avian Influenza Virus Type A Antigen Test Kit

WALTHAM, Mass., Aug. 11 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (Amex: IMA ), a leading provider of near-patient diagnostics, monitoring and health management solutions, announced today that it has received licensure from the United States Department of Agriculture (USDA...

Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases

BOSTON, May 2 /PRNewswire/ -- Replikins Ltd. has found that the replikin concentration of West Nile Virus increased annually through two distinct cycles as the virus expanded in the U.S.: the first from 2000 to 2003, and the second from 2004 to 2007 (p less than 0.001). Increases in the annual...

Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection

ANA598 demonstrates significant antiviral activity in vivo SAN DIEGO, Jan. 3 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced preliminary data today from two studies of ANA598, a non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, in...

Researchers Train the Immune System to Deliver Virus That Destroys Cancer in Lab Models

Procedure also could prevent recurrence ROCHESTER, Minn., Dec. 18 /PRNewswire-USNewswire/ -- An international team of researchers led by Mayo Clinic have designed a technique that uses the body's own cells and a virus to destroy cancer cells that spread from primary tumors to other parts o...

XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis

VALLEY COTTAGE, N.Y., Dec. 10 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB , TASE: XTL) announced today that it will make two scientific presentations related to its pre-clinical Hepatitis C virus (HCV) small molecule program at HEP DART 2007, an international scientifi...

Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies

Data Presented at the 2nd Annual International Workshop on Hepatitis C Resistance & New Compounds WATERTOWN, Mass., Nov. 1 /PRNewswire/ -- Researchers from Enanta Pharmaceuticals today presented data on novel Hepatitis C protease inhibitors with potent antiviral activity...

CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein

VIENNA, Va., Sept. 19 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM ) announces that its CEL-1000 immunomodulator was shown to be able to jump start the immune response against the recombinant hepatitis B virus protein more quickly than did other vaccine adjuvants. This effect in t...

Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses

ANA598 demonstrates favorable preclinical antiviral, metabolic, pharmacokinetic and preliminary toxicologic properties SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) presented preclinical data today on ANA598, a non-nucleoside inhibitor ...

Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche

BRANFORD, Conn., Sept. 6 /PRNewswire/ -- 454 Life Sciences, a Roche company, today announced that researchers at Columbia University, in collaboration with 454, have identified a virus implicated in the deaths of 2.4 million honeybee colonies -- tens of billions of bees -- using the company's ...

Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006

New software will provide first real-time analysis of such infectious-disease outbreaks SEATTLE, Aug. 28 /PRNewswire/ -- In the first systematic, statistical analysis of its kind, infectious-disease-modeling experts at Fred Hutchinson Cancer Research Center confirm ...

Replikins LLC Finds West Nile Virus Replikin Count Has Reached Its Highest Recorded Value

BOSTON, Aug. 3 /PRNewswire/ -- Replikins LLC has discovered a new group of virus structural peptides within virus proteins, called replikins, which provide virus-specific advance quantitative warnings of rapid replication and the risk of epidemics. Replikins LLC has developed software called R...

IBM and EU Partners Create a Better Way to Fight AIDS Virus

EuResist HIV Treatment Prediction Tool Wins Top Honors in Computerworld Honors Program WASHINGTON, June 2 /PRNewswire-FirstCall/ -- IBM (NYSE: IBM ) today announced it was selected for its contributions to the EuResist research project for AIDS treatment as a Computerworld Honors Progra...

Quest Diagnostics Introduces First Commercial Laboratory Test for Identifying the H1N1 Swine Flu Virus

Real-time PCR test validated using clinical specimens confirmed positive for Influenza A H1N1 Swine-origin flu virus MADISON, N.J., May 11 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX ), the world's leading provider of diagnostic testing, information and service...

New Study Shows Probiotic Strain Effective in Boosting Immune Response to Flu Virus

Bacillus coagulans boosts a key immune marker in healthy people CLEVELAND, May 5 /PRNewswire/ -- A new study in the current issue of Postgraduate Medicine suggests that a specific strain of probiotics , Bacillus coagulans GBI-30, PTA-6086, increases the body's immune response to the flu ...

Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus

12 Patient Trial Targets Advanced Solid Tumors, Including Lung Cancer SAN FRANCISCO, Oct. 15 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Canada) today announced the completion of treatment for the first patient cohort in the Phase 1 cancer clinical trial of its targeted poxv...

Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus

Proves promising for individuals living with West Nile Virus and populations susceptible such as the elderly or immune compromised PURCHASE, N.Y., Sept. 9 /PRNewswire/ -- A recently completed study from researchers at Colorado State University supported by the Division of Vector-Borne In...

Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus

Study Demonstrates Feasibility and Efficacy of Treating Patients with Primary Liver Cancer SAN FRANCISCO, and YONGIN-SI, South Korea, July 22 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), and its South Korean partner Green Cross Corp., announ...

Focus Diagnostics Launches Laboratory Test for Chikungunya Virus

First Laboratory Developed Test in the U.S. for Detecting the Mosquito-Borne Infectious Disease CYPRESS, Calif., Feb. 15 /PRNewswire/ -- Focus Diagnostics, Inc., the infectious disease diagnostics company of Quest Diagnostics (NYSE: DGX ), today announced the first labo...

Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus

BOSTON and CARLSBAD, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA ) today announced that data was presented demonstrating the potent activity of the Company's non-nucleoside reverse transcriptase inhibitor (NNRTI) family of compounds against the human-immunod...

ANA380 Exhibits Activity In Vitro Against Multiple Clinically Relevant Hepatitis B Virus Mutants

Poster Presentation at EASL on April 13, 2007, 2007 SAN DIEGO, and SEOUL, South Korea, April 13 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. and LG Life Sciences, Ltd., presented data from an in vitro study showing that ANA380 (LB80380) retains potency against multiple mutant strains of ...

Baraclude (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment

93 Percent of Nucleoside-Naive Chronic Hepatitis B e-Antigen (HBeAg)-Negative Patients Achieved Undetectable Viral Load by Week 48 of Re-Treatment PRINCETON, N.J., April 13, 2007 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company today announced data from a cohort of nucleoside-naive HBeAg-neg...

St. Jude Study Shows Effectiveness of Peramivir in Prevention of Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection

BioCryst Says Study Confirms and Extends Evidence Seen in a Previous Study BIRMINGHAM, Ala., May 02, 2007 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced that investigators at St. Jude Children's Research Hospital, Memphis, TN, reported favorable results evaluating peramiv...

Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 6, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Study 102, a Phase III clinical trial evaluating the company's once-daily anti-HIV drug Viread (tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment for chronic hep...

Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection

SAN DIEGO, June 20, 2007 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. , a biopharmaceutical company committed to the discovery, development and commercialization of novel medicines for the treatment of hepatitis and cancer, announced today that it has nominated ANA598 as a candidate for ...

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Study 103, a Phase III clinical trial evaluating the company's once-daily anti-HIV drug Viread(R) (tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment for chronic...

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--June 25, 2007--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Study 103, a Phase III clinical trial evaluating the company's once-daily anti-HIV drug Viread(R) (tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment for chroni...

Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types

Results also show significant additional protection against infection with virus types beyond 16 and 18 with the GSK cervical cancer candidate vaccine PHILADELPHIA, June 27, 2007 /PRNewswire-FirstCall/ -- Results from an interim analysis of a Phase III study show that CERVARIX(R), the GlaxoSmithKl...

European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGene's Cancer-Killing Virus in Press Conference

* Presentation of efficacy trends from ongoing phase I/II trial of oncolytic HSV * Poster selected by ESMO for presentation in press conference MARTINSRIED, Germany, June 29, 2007.--The biotech company MediGene AG (Frankfurt, Prime Standard: MDG) announces that a case report from the ongoing...

MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial

MARTINSRIED/MUNICH, Germany, July 9, 2007-A virus that has been specifically designed by scientists to be safe to normal tissue but deadly to cancer is showing early promise in a preliminary study, researchers said today at the ESMO Conference Lugano (ECLU), Switzerland. The virus, called NV1020...

West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak

Helen Londe, M.D. Contributing Editor The first human case of West Nile virus (WNV) for 2005 was reported to have occurred in Kansas in late June. The CDC has released few details on the patient but has confirmed this being 2005's first documented incidence of the mosquito borne disease in the US...

CytoGenix Announces Successful Testing of synDNA Vaccine for Avian Influenza Virus

HOUSTON--(BUSINESS WIRE)--Apr 4, 2007 - CytoGenix, Inc. (CYGX.OB) announced today that it has successfully completed an important pilot study with a novel synDNA(TM) vaccine designed for humans (therapeutic) and intended to protect against the avian (H5N1) influenza virus. The study clearly demonst...